Skip to main content

SR One — Portfolio, Page 3

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

64
Companies
$6.7B
Total invested
$105.0M
Avg. check
15
Industries
Biotechnology 14Health Care 8Therapeutics 6Medical 5Life Science 4Medical Device 3+9 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 49–64 of 64
Morphic Therapeutic
May 2023

Morphic Therapeutic is a biotechnology company that develops oral integrin therapies to treat serious chronic diseases.

Biotechnology · Waltham$276.0M Post Ipo Equity
Pulmocide
December 2022

Pulmocide is focused on the development of inhaled medicines for the treatment of viral and fungal infections of the respiratory tract.

Biotechnology · London$52.0M Series C
Spero Therapeutics
September 2022

Spero Therapeutics develops therapeutics for treatment of gram-negative infections.

Biotechnology · Cambridge$9.0M Post Ipo Equity
MiroBio
June 2022

MiroBio is Harnessing the natural control mechanisms of the immune system.

Biotechnology · Oxford$97.0M Series B
Ancora Biotech
June 2022

Ancora Biotech is a privately held company supporting the clinical development of three multi-specific antibodies.

Biotechnology · Palo Alto$60.0M Series A
River 2 Renal
January 2021

River 2 Renal is a developer of novel therapies intended to cure orphan diseases.

Health Care · New York$40.0M Series A
Decibel Therapeutics
November 2020

Decibel Therapeutics is a hearing company focused on discovering and developing new medicines to protect, repair, and restore hearing.

Biotechnology · Cambridge$82.2M Series D
Turning Point Therapeutics
October 2020

Turning Point Therapeutics is a pharmaceutical company that discovers and develops precision medicines for cancer and other diseases.

Biotechnology · San Diego$460.0M Post Ipo Equity
Palleon Pharmaceuticals
September 2020

Palleon Pharmaceuticals is a developer of a biotechnology platform designed to offer glycoimmune checkpoint inhibitors to treat cancer.

Biotechnology · Waltham$100.0M Series B
Tranquis Therapeutics
July 2020

Tranquis Therapeutics is focused on the discovery and development of therapies to treat neurodegenerative and aging-related diseases.

Biotechnology · San Mateo$30.0M Series A
Translate Bio
January 2020

Translate Bio is a biotechnology company that specializes in biotechnology, RNA therapeutics, and rare diseases.

Biotechnology · Lexington$125.0M Post Ipo Equity
Gladius Pharmaceuticals
November 2018

Gladius Pharmaceuticals is a biotechnology firm developing novel drugs to treat life-threatening

Biotechnology · MontréalSeries Unknown
Gotham Therapeutics
October 2018

Gotham Therapeutics is discovering a novel drug class targeting the epitranscriptomics machinery.

Biotechnology · New York$54.0M Series A
ZappRx
April 2017

ZappRx is a digital health company that is modernizing and simplifying the way specialty drugs are ordered

Health Care · Boston$25.0M Series B
Atopix Therapeutics
November 2016

Atopix Therapeutics Limited is a privately held, clinical-stage, biopharmaceutical company based in Oxford, UK

Biotechnology · AbingdonSeries Unknown
Puridify
August 2016

Puridify conducts research and development activities on bioprocessing technologies aimed at advancing industrial biomolecule manufacture.

Biotechnology · Stevenage$56K Grant

Where SR One invests

Biotechnology14
Health Care8
Therapeutics6
Medical5
Life Science4
Medical Device3

About SR One's portfolio

How many companies has SR One invested in?▸

SR One has invested in 64 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does SR One invest in?▸

SR One's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Life Science. The firm invests across 15 different industry categories.

What is SR One's largest investment?▸

Among tracked funding rounds, Turning Point Therapeutics received $460.0M in a Post Ipo Equity round. SR One's total known invested capital is $6.7B.

What is the average investment size for SR One?▸

SR One's average investment size is $105.0M across its portfolio of 64 companies.

What are SR One's most recent investments?▸

Recent SR One portfolio additions include Morphic Therapeutic, Pulmocide, Spero Therapeutics, MiroBio, Ancora Biotech. These companies were founded in 2020 or later.

Reach the founders behind these 64 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →